4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals. Researchers from Istanbul, Turkey, conducted a study that found ...

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428). Clinical data from the Phase 1/2a clinical trial evaluating RPESC-RPE-4W was presented ...

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the latest innovations in anti-VEGF therapy, tailored to retina specialists ...

Miguel A. Quiroz-Reyes, MD, PhD, and colleagues found that cigarette smoking negatively affects the choroidal vascularity, as indicated by a significant reduction of the choroidal vascularity index ...

Pykus Therapeutics has secured a new patent from the United States Patent and Trademark Office entitled "Hydrogel Formulations and Methods and Devices for Administration of the Same" (US Patent No. 12 ...

The intent is that the board provide strategic guidance and expert insights to support the development of the company’s programs and science. Alkeus Pharmaceuticals has established a new Scientific ...